Home / Intelligence / Case Studies / Cross-Functional Launch Strategy Alignment Workshop
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope: 
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC and mCRC treatment paradigm, as well as oncology regulatory landscape in Japan.
Trinity then organized a full-day day workshop at the client’s local office in Japan to enable cross functional client teams to collaborate on forecasting assumptions and optimal launch strategies.
Deliverables
- Case studies of oncology analogues and recent pricing outcomes in JPN
- In-depth policy review of JPN’s new health technology assessment (HTA) process
- Final report with detailed summary of workshop outputs
- Final launch pricing and commercial strategy
Project Outcomes & Impact:
The workshop generated the opportunity for the client’s local team to deliver nuanced local expertise and strategic insights to the global team to ensure that the updated launch forecast model included realistic access assumptions.
Related Intelligence
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More
Blog
Early China Launch of PIASKY® in the Fight Against PNH
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the […]
Read More